Drug intelligence / Profile preview

MDT-10013

Development stage: Discontinued
Lead developer: Medtronic
Modality: Small Molecules

Overview

MDT-10013 is a small molecule analgesic that was developed by Medtronic, specifically its Spinal and Biologics division, for the treatment of acute postoperative pain. The drug was investigated in phase II clinical trials for use following procedures such as bunionectomy and total knee arthroplasty. Its precise mechanism of action has not been defined or disclosed publicly. Development of MDT-10013 has since been discontinued, with no recent reports of ongoing clinical activity or further development[1][2][5].

Other names: MDT 10013MDT10013MDT-10013

Beyond the preview

Go deeper on MDT-10013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDT-10013.

Explore the full profile